High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations

• Verfasst von: Edelmann, Jennifer [VerfasserIn]
• Verfasst von: Zenz, Thorsten [VerfasserIn]
• Verfasst von: Lichter, Peter [VerfasserIn]
• Titel: High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations
• Verf.angabe: Jennifer Edelmann, Karlheinz Holzmann, Florian Miller, Dirk Winkler, Andreas Bühler, Thorsten Zenz, Lars Bullinger, Michael W. M. Kühn, Andreas Gerhardinger, Johannes Bloehdorn, Ina Radtke, Xiaoping Su, Jing Ma, Stanley Pounds, Michael Hallek, Peter Lichter, Jan Korbel, Raymonde Busch, Daniel Mertens, James R. Downing, Stephan Stilgenbauer, and Hartmut Döhner
• E-Jahr: 2012
• Jahr: October 09, 2012
• Umfang: 12 S.
• Fussnoten: Gesehen am 18.04.2019
• Titel Quelle: Enthalten in: Blood
• Ort Quelle: Washington, DC : American Society of Hematology, 1946
• Jahr Quelle: 2012
• Band/Heft Quelle: 120(2012), 24, Seite 4783-4794
• ISSN Quelle: 1528-0020
• DOI: doi:10.1182/blood-2012-04-423517
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 166344093X

Abstract

To identify genomic alterations in chronic lymphocytic leukemia (CLL), we performed single-nucleotide polymorphism-array analysis using Affymetrix Version 6.0 on 353 samples from untreated patients entered in the CLL8 treatment trial. Based on paired-sample analysis (n = 144), a mean of 1.8 copy number alterations per patient were identified; approximately 60% of patients carried no copy number alterations other than those detected by fluorescence in situ hybridization analysis. Copy-neutral loss-of-heterozygosity was detected in 6% of CLL patients and was found most frequently on 13q, 17p, and 11q. Minimally deleted regions were refined on 13q14 (deleted in 61% of patients) to the DLEU1 and DLEU2 genes, on 11q22.3 (27% of patients) to ATM, on 2p16.1-2p15 (gained in 7% of patients) to a 1.9-Mb fragment containing 9 genes, and on 8q24.21 (5% of patients) to a segment 486 kb proximal to the MYC locus. 13q deletions exhibited proximal and distal breakpoint cluster regions. Among the most common novel lesions were deletions at 15q15.1 (4% of patients), with the smallest deletion (70.48 kb) found in the MGA locus. Sequence analysis of MGA in 59 samples revealed a truncating mutation in one CLL patient lacking a 15q deletion. MNT at 17p13.3, which in addition to MGA and MYC encodes for the network of MAX-interacting proteins, was also deleted recurrently.